IMpassion132: Learning From Immunotherapy’s Failures in Early Relapsing Triple-Negative Breast Cancer
IMpassion132, a phase 3 trial of chemotherapy plus immune checkpoint inhibition in triple-negative breast cancer, was negative; however, it provided informative results for an understudied population with a poor prognosis.